intravenous cbd

Intake of trans-Cannabidiol results in wellbeing, feeling fitness and homeostasis in general. The applicant suggests a daily intake of trans-Cannabidiol of 50 mg per average adult, i.e. 0.71 mg/kg b.w.

Chanelle McCoy CBD LTD 1 Summary of the dossier: Cannabidiol Applicant: Chanelle McCoy CBD LTD, Chanelle House, Barrack Street, Loughrea, Co. Galway, H62 YX07, Ireland Chanelle McCoy CBD LTD (“Chanelle”) has prepared an application for authorisation of cannabidiol (CBD) as a novel food ingredient in the European Union (EU).

Commission Implementing Decision of 8.12.2021 terminating the procedure for authorising the placing on the market within the Union of the novel food ‘cannabidiol’ without updating the Union list of novel foods pursuant to Regulation (EU) 2015/2283 of the European Parliament and of the Council (C(2021) 8830 final).

Improving drug treatment for schizophrenia

Chanelle McCoy CBD LTD 1 Summary of the dossier: Cannabidiol Applicant: Chanelle McCoy CBD LTD, Chanelle House, Barrack Street, Loughrea, Co. Galway, H62 YX07, Ireland Chanelle McCoy CBD LTD (“Chanelle”) has prepared an application for authorisation of cannabidiol (CBD) as a novel food ingredient in the European Union (EU).

Therefore, the latter product should be considered a feed additive. • Cannabidiol oil : Vegetable products from oil manufacture obtained by supercritical CO2 extraction, such as Cannabidiol oil extracted from hemp flowers (Cannabis sativa L.) and successively purified and standardised, should rather be considered feed additives than feed materials.

6445bf52-d43b-40bc-97a7-d29fbf06841e_en

Already since the 1970s it was shown that oral cannabidiol, intravenous injections, and inhalation of cannabidiol did not lead to any adverse effects and showed an excellent safety profile.

Public summary of the dossier: Synthetic Cannabidiol (CBD). Applicant: Farmabios S.p.A. Via Pavia, 1 – 27027 Gropello Cairoli, (PV), Italy.

Intravenous cbd

Crystalline form CBD (preliminary experiments) or ethanolic solutions of CBD and THC (confirmatory and replication studies) were loaded onto the vaporiser filling chamber via a liquid pad – a removable disc made of tightly packed stainless steel wire mesh – as supplied by the manufacturer of the Volcano®. For the confirmatory and replication studies, the desired dose of cannabinoids (see Table 1) was applied in aliquots of maximum 400 μl, in order to prevent overloading of the liquid pad, which may result in leaking. After each application, ethanol was evaporated using the Volcano® vaporiser set at 100°C for 30 seconds. THC and CBD (with boiling points well over 160°C) were not affected by this treatment, and remained as pure compounds on the liquid pad. Before each new experiment the filling chamber was thoroughly cleaned with ethanol and allowed to dry at ambient temperature. A new liquid pad was used for each experiment.

Trial registration

Hazekamp A, Simons R, Peltenburg-Looman A, Sengers M, Van Zweden R, Verpoorte R: Preparative isolation of cannabinoids from Cannabis sativa by centrifugal partition chromatography. J Liquid Chromat Rel Technol. 2004, 27: 2421-2439. 10.1081/JLC-200028170.

Endnote

The results from the series of studies conducted indicate that with small doses of CBD, such as the 4 mg we applied, 97.5% may be delivered into the balloon following vaporisation. With THC (8 mg) up to 80% of the dose loaded was delivered into the balloon, substantially greater than the 54% previously reported [11], possibly due to improvements in the heating efficiency of the vaporiser. With high dose CBD, only about 40% of the dose was delivered, indicating that evaporation does not increase linearly with the loaded dose. An optimal dose of 200 mg CBD can be effectively and efficiently vaporised to deliver approximately 80 mg of CBD. Human research participants may be asked to inhale two normal size balloons (standard with the Volcano® vaporiser) to achieve a combined dose of approximately 160 mg. A larger dose may be delivered if the CBD is vaporised into larger (XL) balloons, but these are 1.5 times larger than the normal size balloons, requiring significantly more inhalations, while the resultant dose delivered is not 1.5 times greater. The presence of both compounds reduces the delivery of each when the dose of CBD is high, likely due to saturation effects in the vapour. Further adjustments could potentially be made to vaporisation protocols and the doses loaded to try to better achieve the desired dose delivered. For example, we opted to have participants inhale two standard size balloons to maximise the dose of CBD delivered, judging it to be impracticable to have participants inhale two XL size balloons (because of their large volume and the time restraints and other demands on participants in our RCT); for other experiments researchers may opt to use one or two XL size balloons and achieve greater dosing by this means, with less wastage of the CBD dose loaded. Further, using our data reported above, in order to compare the effects of loaded doses of 8 mg THC and 400 mg CBD in combination, with the effects of each compound separately, we opted to load the vaporiser with 8 mg THC and 200 mg CBD for delivery into the first balloon (vaporised to deliver approximately 4.4 mg THC and 74 mg CBD), and we loaded 4 mg THC and 200 mg CBD for delivery into the second balloon (vaporised to deliver 2.2 mg THC and 78 mg CBD). The total doses delivered from these two balloons equal 6.6 mg THC and 152 mg CBD; this achieved equivalence broadly with the 6.2 mg THC and 163 mg CBD delivered when each compound was delivered separately. Alternatively, THC and CBD could be loaded and vaporised separately into two balloons that the participant inhales sequentially, but this could result in quite different pharmacokinetic and pharmacodynamic effects compared to simultaneous administration of the two compounds and the methodology depends upon the questions to be addressed in the research.